BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.48B | 122.82M | 138.18M | 1.06B | 1.78B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.48B | 122.82M | 138.18M | 1.06B | 1.78B |
| Cost of Revenue | 105.78M | 112.82M | 83.54M | 352.49M | 173.38M |
| Gross Profit | 1.38B | 10.00M | 54.64M | 703.81M | 1.60B |
| SG&A Expenses | 205.45M | 230.06M | 176.44M | 253.66M | 173.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 57.44M | 215.75M | 23.28M | 214.08M | 786.81M |
| Total Operating Expenses | 1.03B | 1.11B | 934.96M | 1.41B | 1.69B |
| Operating Income | 449.35M | -990.71M | -796.78M | -352.26M | 81.49M |
| Income Before Tax | 255.52M | -998.74M | -664.68M | -264.72M | 28.88M |
| Income Tax Expenses | 43.16M | -44.08M | -42.35M | 90.33M | 62.43M |
| Earnings from Continuing Operations | 212.36M | -954.66M | -622.33M | -355.05M | -33.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 212.36M | -954.66M | -622.33M | -355.05M | -33.55M |
| EBIT | 449.35M | -990.71M | -796.78M | -352.26M | 81.49M |
| EBITDA | 831.83M | -681.22M | -654.85M | -310.76M | 226.69M |
| EPS Basic | 0.85 | -3.77 | -2.46 | -1.46 | -0.14 |
| Normalized Basic EPS | 1.35 | -2.23 | -1.64 | -0.62 | 0.32 |
| EPS Diluted | 0.84 | -3.77 | -2.46 | -1.46 | -0.14 |
| Normalized Diluted EPS | 1.33 | -2.23 | -1.64 | -0.62 | 0.32 |
| Average Basic Shares Outstanding | 249.32M | 253.33M | 253.29M | 244.00M | 239.17M |
| Average Diluted Shares Outstanding | 252.74M | 253.33M | 253.29M | 244.00M | 239.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |